Epimab Biotherapeutics Inc., of Shanghai, licensed the rights to its Fabs-In-Tandem Immunoglobulin program, FIT-012/TRS-008, in the Chinese market to Zhejiang Teruisi Biopharmaceutical Inc., of Huzhou, China. Epimab is eligible to receive an up-front payment and total success-based milestones of up to $21 million plus royalties on FIT-012/TRS-008, a bispecific antibody to undisclosed targets. Epimab has rights to use data generated by Zhejiang Teruisi in partnering discussions outside of China for an undisclosed share of its net receipts.